Ovid Therapeutics Files Q1 2025 10-Q
Ticker: OVID · Form: 10-Q · Filed: May 13, 2025 · CIK: 1636651
| Field | Detail |
|---|---|
| Company | Ovid Therapeutics Inc. (OVID) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Ovid Therapeutics filed its Q1 2025 10-Q. Financials look steady.
AI Summary
Ovid Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including common stock and preferred stock activity. The company's principal executive offices are located at 441 Ninth Avenue, 14th Floor, New York, NY 10001.
Why It Matters
This filing provides investors with the latest financial performance and structural details of Ovid Therapeutics, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: low — The filing is a standard quarterly report and does not contain immediate red flags.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 20250513 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Ovid Therapeutics Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 441 NINTH AVENUE, 14TH FLOOR (address) — Company's business and mailing address
- NEW YORK, NY 10001 (address) — Company's business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 13, 2025.
What is the primary business address of Ovid Therapeutics Inc.?
The primary business address of Ovid Therapeutics Inc. is 441 Ninth Avenue, 14th Floor, New York, NY 10001.
What is the fiscal year end for Ovid Therapeutics Inc.?
The fiscal year end for Ovid Therapeutics Inc. is December 31.
What type of stock activity is mentioned for the period ending March 31, 2025?
The filing mentions activity related to Series A Preferred Stock and Common Stock for the period ending March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Ovid Therapeutics Inc. (OVID).